CD274 and neoplasm: In the tumor PD-L1 ≥ 1%, tumor PD-L1 < 1%, and the combined PD-L1 ≥ 1% and < 1% populations, the median (range) treatment durations were 6.0 (0–24.0), 4.2 (0–24.0), and 5.1 (0–24.0) months for nivolumab plus ipilimumab versus 4.2 (0–49.4), 2.3 (0–24.3), and 3.8 (0–49.4) months for chemotherapy, respectively (Table 2).